| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/03/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/24/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 07/19/2023 |
8-K
| Quarterly results |
| 07/11/2023 |
SC 13D/A
| Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC. |
| 07/11/2023 |
8-K
| Resignation/termination of a director|
Docs:
|
"CREDIT AND SECURITY AGREEMENT Credit and Security Agreement, dated as of July 10, 2023, by and among Armata Pharmaceuticals, Inc., a Washington corporation , each Subsidiary of the Borrower listed as a “Guarantor” on the signature pages hereto , each a “ Guarantor ” and collectively, the “ Guarantors ”) and Innoviva Strategic Opportunities LLC, a Delaware limited liability company, or an affiliate thereof, as the lender . In consideration of the premises and the covenants and agreements contained herein, the parties hereto agree as follows: ARTICLE I DEFINITIONS; CERTAIN TERMS Section 1.01.     Definitions . As used in this Agreement, the following terms shall have the respective meanings indicated below:",
"FIRST AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT",
"Amendment No. 1 to THE Second AMENDED AND RESTATED voting agreement",
"Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics" |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/06/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 03/28/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 03/16/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/13/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 01/10/2023 |
SC 13D/A
| Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC. |
| 01/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/19/2022 |
8-K
| Quarterly results |
| 11/18/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/17/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 09/20/2022 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/01/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/31/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/13/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/07/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/06/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 04/01/2022 |
SC 13D/A
| Innoviva, Inc. reports a 80.1% stake in ARMATA PHARMACEUTICALS, INC. |
|